DDInter1620 DDInter1925
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Ropivacaine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Ropivacaine {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ropivacaine {u} (Compound) downregulates {v} (Gene) NSDHL
NSDHL {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Ropivacaine {u} (Compound) upregulates {v} (Gene) MLLT11
MLLT11 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Ropivacaine {u} (Compound) causes {v} (Side Effect) Myalgia
Myalgia {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Ropivacaine {u} (Compound) resembles {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vemurafenib
Ropivacaine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Ropivacaine {u} (Compound) upregulates {v} (Gene) MAL
MAL {u} (Gene) is regulated by {v} (Gene) PAN2
PAN2 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ropivacaine {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is regulated by {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Vemurafenib
Ropivacaine {u} (Compound) downregulates {v} (Gene) NSDHL
NSDHL {u} (Gene) is regulated by {v} (Gene) ORM1
ORM1 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Ropivacaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Ropivacaine (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Vemurafenib (Compound)
Ropivacaine (Compound) downregulates NSDHL (Gene) and NSDHL (Gene) is downregulated by Vemurafenib (Compound)
Ropivacaine (Compound) upregulates MLLT11 (Gene) and MLLT11 (Gene) is downregulated by Vemurafenib (Compound)
Ropivacaine (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Vemurafenib (Compound)
Ropivacaine (Compound) resembles Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Ropivacaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Ropivacaine (Compound) upregulates MAL (Gene) and MAL (Gene) is regulated by PAN2 (Gene) and PAN2 (Gene) is upregulated by Vemurafenib (Compound)
Ropivacaine (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is regulated by ALB (Gene) and ALB (Gene) is bound by Vemurafenib (Compound)
Ropivacaine (Compound) downregulates NSDHL (Gene) and NSDHL (Gene) is regulated by ORM1 (Gene) and ORM1 (Gene) is bound by Vemurafenib (Compound)